ZYNE Zynerba Pharmaceuticals Inc.

-0.82  -7%
Previous Close 12.39
Open 12.49
Price To Book 3.12
Market Cap 156905086
Shares 13,561,373
Volume 1,498,097
Short Ratio 11.33
Av. Daily Volume 241,061

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 1 trial to be completed 1H 2018 with a Phase 2 trial to be initiated 2H 2018.
Tourette Syndrome
Development to be discontinued - noted January 2018.
Development to be discontinued - noted January 2018.
Peripheral Neuropathic Pain (PNP)
Phase 2 data released September 28, 2017. Company noted data were positive with primary endpoint met. Data to be presented July 12, 2018. Pivotal trial to commence mid-2018 with data due 2019.
Fragile X syndrome
Phase 2 data released August 14, 2017 - primary endpoint not met. Noted January 2018 that development will be discontinued.
Phase 2 data released August 7, 2017 - endpoints not met. Phase 2b trial to be initiated 2H 2018.
ZYN002 - STAR 1
Adult Epilepsy Patients with Refractory Focal Seizures
Phase 2 trial to be initiated 1H 2018 with data due 2019.
Developmental and Epileptic Encephalopathies (DEE)

Latest News

  1. Zynerba Pharmaceuticals to Present at the Jefferies 2018 Global Healthcare Conference
  2. The Tech Revolutionizing The Billion Dollar Marijuana Business
  3. Pot Stock Winners of the Week
  4. Interested In Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)? Here’s How It Performed Recently
  5. Zynerba: 1Q Earnings Snapshot
  6. Zynerba Pharmaceuticals Reports First Quarter 2018 Financial Results and Operational Highlights
  7. Zynerba Pharmaceuticals Announces Twelve Month ZYN002 Data from STAR 2 Study in Patients with Focal Seizures at the 2018 Annual Meeting of the American Academy of Neurology (AAN)
  8. Zynerba Pharmaceuticals Announces Oral Presentation of ZYN002 Data at the 16th NFXF International Fragile X Conference in July 2018
  9. What Do Analysts Think About Zynerba Pharmaceuticals Inc’s (NASDAQ:ZYNE) Earnings Trend?
  10. Can Cannabis Treat Seizures? Biotechs Say The Answer Is Yes
  11. Zynerba Pharmaceuticals Appoints John P. Butler to Board of Directors
  12. Zynerba Pharmaceuticals Initiates Open-Label Phase 2 Trial of ZYN002 in Developmental and Epileptic Encephalopathies (DEE)
  13. Should You Buy Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE) At $7.98?
  14. Zynerba Pharmaceuticals Announces Publication of Preclinical Data in Neuropsychopharmacology Demonstrating Effect of Cannabidiol Gel Treatment in Reduction of Relapse in an Addiction Model
  15. Analysts Expect Breakeven For Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE)
  16. Today’s Research Reports on Trending Tickers: Kura Oncology and Zynerba Pharmaceuticals
  17. Zynerba reports 4Q loss